Evidence map›Paper›PMID 32071713›Full record

ReviewCell & bioscience2020

Ubiquitin and ubiquitin-like molecules in DNA double strand break repair.

Jia Yu, Bo Qin, Zhenkun Lou

Abstract readReview
In one paragraph

Review in Cell & bioscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. P38 kinase in gastrointestinal cancers.Cancer gene therapy · 2023
    Review
  13. Article
  14. The ATM-E6AP-MASTL axis mediates DNA damage checkpoint recovery.bioRxiv : the preprint server for biology · 2023
    Article
  15. Ubiquitination Links DNA Damage and Repair Signaling to Cancer Metabolism.International journal of molecular sciences · 2023
    Review
  16. Review
  17. DNA Damage Response Regulation by Histone Ubiquitination.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jia Yu1Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Bo Qin1Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Zhenkun Lou2Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA.

Funding

Ubiquitination and the DNA Damage Response PathwayR01CA130996 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2008 to 2018
$3.3M
Regulation of homologous recombination and cancer cell response to chemoradiotherapyR01CA203561 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2016 to 2020
$1.8M
UFM1 signaling in DNA damage response and cancer therapyR01CA217183 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2018 to 2022
$1.8M
NCI NIH HHS R01 CA130996NCI NIH HHS R01 CA203561NCI NIH HHS R01 CA217183
6 · The paper itself

Abstract

Both environmental and endogenous factors induce various forms of DNA damage. DNA double strand break (DSB) is the most deleterious DNA lesion. The swift initiation of a complexed network of interconnected pathways to repair the DNA lesion is essential for cell survival. In the past years, the roles of ubiquitin and ubiquitin-like proteins in DNA damage response and DNA repair has been explored. These findings help us better understand the complicated mechanism of DSB signaling pathways.

Indexed as

DNA damageDNA repairDouble strand breakUbiquitinUbiquitin-like protein

Identifiers

PMID32071713
PMCPMC7014694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.